Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

ADMA Biologics Inc ADMA

Healthcare  —  Biotechnology
9.38 (0.14) (1.47%) as of 25 Sep
Market cap
$2.1B
P/E
13.0×
Revenue Champion (5y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

ADMA Biologics Inc (ADMA) Business Profile

Updated before January 2025

Company Overview

ADMA Biologics Inc. (ADMA) is a publicly traded biopharmaceutical company specializing in the development, manufacturing, and commercialization of plasma-derived biologics. Founded in 2004 and headquartered in Ramsey, New Jersey, ADMA focuses on addressing unmet medical needs in the field of immunology and infectious diseases. The company was co-founded by Adam Grossman, who currently serves as the President and Chief Executive Officer. Under his leadership, ADMA has grown into a key player in the plasma-derived therapeutics industry, with a strong emphasis on innovation and patient care.

ADMA operates state-of-the-art manufacturing facilities and plasma collection centers across the United States. The company is committed to producing high-quality, life-saving therapies for patients with immune deficiencies and other medical conditions. ADMA’s leadership team comprises experienced professionals with extensive expertise in biotechnology, pharmaceuticals, and healthcare, ensuring the company remains at the forefront of its industry.

Core Business Segments

ADMA Biologics operates primarily in the plasma-derived therapeutics market. Its core business segments include:

1. Plasma-Derived Products

ADMA’s flagship products are derived from human plasma and are designed to treat immune deficiencies and other conditions. Key products include:

  • ASCENIV™: A specialty immune globulin product used to treat primary humoral immunodeficiency disease (PI).
  • BIVIGAM®: An intravenous immune globulin (IVIG) product indicated for the treatment of primary immunodeficiency (PI).
  • Nabi-HB®: A hyperimmune globulin used to prevent hepatitis B infection in specific patient populations.

2. Plasma Collection Centers

ADMA operates a network of FDA-licensed plasma collection centers under the brand “ADMA BioCenters.” These centers collect high-quality plasma, which serves as the raw material for the company’s therapeutic products. The plasma collection segment is a critical component of ADMA’s vertically integrated business model.

3. Contract Manufacturing and Services

ADMA also provides contract manufacturing services to other biopharmaceutical companies. This includes plasma fractionation, fill-finish services, and other related activities. These services generate additional revenue streams while leveraging the company’s manufacturing capabilities.

Business Model

ADMA Biologics employs a vertically integrated business model that combines plasma collection, product development, manufacturing, and commercialization. This approach allows the company to control the entire value chain, from sourcing raw materials to delivering finished products to patients. Key aspects of ADMA’s business model include:

  • Plasma Collection: ADMA’s BioCenters ensure a consistent and high-quality supply of plasma for its products.
  • Product Development: The company invests heavily in research and development to create innovative therapies that address unmet medical needs.
  • Manufacturing: ADMA operates FDA-approved manufacturing facilities, enabling it to produce its products in-house and maintain strict quality control.
  • Commercialization: The company markets its products directly to healthcare providers and distributors, ensuring broad access for patients.

Revenue is primarily generated through the sale of plasma-derived products, contract manufacturing services, and plasma collection activities.

Strategic Direction

ADMA Biologics has outlined several strategic priorities to drive future growth and sustainability:

  • Expansion of Plasma Collection Centers: The company plans to increase the number of ADMA BioCenters to secure a larger supply of plasma and meet growing demand for its products.
  • Pipeline Development: ADMA is actively working on expanding its product portfolio, including new plasma-derived therapies and potential indications for existing products.
  • Operational Efficiency: The company aims to optimize its manufacturing processes to reduce costs and improve margins.
  • Global Expansion: ADMA is exploring opportunities to expand its presence in international markets, leveraging its expertise in plasma-derived therapeutics.
  • Sustainability Goals: The company is committed to minimizing its environmental impact by adopting sustainable practices in its operations.

Competitive Landscape

ADMA Biologics operates in a highly competitive market, facing competition from both large pharmaceutical companies and smaller biopharmaceutical firms. Key competitors include:

  • Grifols: A global leader in plasma-derived products and transfusion medicine.
  • CSL Behring: A major player in the plasma therapeutics industry, offering a wide range of products.
  • Kedrion Biopharma: Specializes in plasma-derived therapies for rare diseases.
  • Octapharma: Focuses on developing and manufacturing human proteins from plasma and cell lines.

ADMA differentiates itself through its vertically integrated business model, focus on niche markets, and commitment to innovation.

Risk Factors

Like any biopharmaceutical company, ADMA Biologics faces several risks that could impact its business:

  • Market Dependence: The company’s revenue is heavily reliant on the sales of a few key products.
  • Regulatory Risks: ADMA operates in a highly regulated industry, and any delays or issues with regulatory approvals could affect its operations.
  • Supply Chain Disruptions: Dependence on plasma collection and manufacturing facilities makes the company vulnerable to supply chain disruptions.
  • Competition: Intense competition from larger, well-established companies could impact market share.
  • Financial Risks: As a growing company, ADMA may face challenges related to funding its operations and achieving profitability.

Recent Developments

ADMA Biologics has made significant progress in recent years, including:

  • Expansion of Plasma Collection Centers: The company has opened new ADMA BioCenters to increase plasma supply.
  • Regulatory Approvals: ADMA received FDA approval for expanded manufacturing capacity, enabling it to meet growing demand for its products.
  • Partnerships and Collaborations: The company has entered into strategic partnerships to enhance its product offerings and expand its market reach.
  • COVID-19 Impact: The global pandemic highlighted the importance of plasma-derived therapies, leading to increased demand for ADMA’s products.

Investment Considerations

Investors considering ADMA Biologics should weigh the following factors:

Strengths

  • Vertically integrated business model ensures control over the value chain.
  • Strong product portfolio addressing unmet medical needs.
  • Growing demand for plasma-derived therapies.
  • Experienced leadership team with a track record of success.

Risks

  • Dependence on a few key products for revenue.
  • Regulatory and supply chain risks.
  • Intense competition from larger players.
  • Financial challenges associated with scaling operations.

Conclusion

ADMA Biologics Inc. is a dynamic biopharmaceutical company with a strong focus on plasma-derived therapies. Its vertically integrated business model, innovative product portfolio, and strategic growth initiatives position it well for future success. While the company faces challenges such as competition and regulatory risks, its commitment to addressing unmet medical needs and expanding its operations makes it an attractive option for investors seeking exposure to the biopharmaceutical sector.